Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.11 AUD
Change Today +0.005 / 5.00%
Volume 346.8K
TIS On Other Exchanges
As of 2:10 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

tissue therapies ltd (TIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/15/14 - A$0.46
52 Week Low
03/26/15 - A$0.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TISSUE THERAPIES LTD (TIS)

Related News

No related news articles were found.

tissue therapies ltd (TIS) Related Businessweek News

No Related Businessweek News Found

tissue therapies ltd (TIS) Details

Tissue Therapies Limited, a biomedical technology company, researches, develops, and commercializes biomedical technologies for chronic wound healing and tissue regeneration worldwide. The company commercializes VitroGro ECM, a biomimetic scaffold comprising a synthetic extracellular matrix protein that replaces the degraded matrix of a hard to heal wounds for the patients and the healthcare providers. It develops treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns, as well as treatments for psoriasis, scar prevention, and various cancers, such as breast, colon, and prostate. Tissue Therapies Limited is headquartered in Brisbane, Australia.

tissue therapies ltd (TIS) Top Compensated Officers

Chief Financial Officer and Company Secretary
Total Annual Compensation: A$174.4K
Compensation as of Fiscal Year 2014.

tissue therapies ltd (TIS) Key Developments

Tissue Therapies Limited Announces Management Changes

The Board of Tissue Therapies Limited announced that the company's CEO, Dr. Steven Mercer, has resigned from the company effective as of April 7, 2015. The Board has appointed Mr. Nigel Johnson, the current Operations Director as acting CEO. Mr. Johnson has been involved in key roles within Tissue Therapies for over 10 years and has a thorough knowledge of the challenges facing Tissue Therapies in its planning for both European and US approval for its lead product VitroGro ECM. The Board will immediately commence an extensive CEO recruitment process. Once a CEO has been appointed, Mr. Johnson will resume his role as Operations Director. The current Chairman, Mr. Roger Clarke has announced that he will stand down as Chairman, and will continue in the role of non-executive Director on the Board in the short-term. The Board has appointed Dr. Cherrell Hirst as interim Chairman who, working with the other Directors, will lead the search for a CEO and a new Chairman.

Tissue Therapies Ltd. Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Tissue Therapies Ltd. reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported income from continuing operations of AUD 79,489 compared to AUD 70,072 a year ago. Loss before income tax benefit was AUD 5,213,093 compared to AUD 3,569,734 a year ago. Net loss after tax was AUD 5,030,939 compared to AUD 3,265,000 a year ago. Loss attributable to members of the company was AUD 5,030,939 or 1.91 cents per basic and diluted share compared to AUD 3,265,000 or 1.48 cents per basic and diluted share a year ago. Net cash used in operating activities was AUD 4,230,449 compared to AUD 3,975,476 a year ago. Payment for property, plant and equipment was AUD 3,950 compared to AUD 4,683 a year ago.

Tissue Therapies Ltd. Appoints Timothy Hughes as Non-Executive Director

Tissue Therapies Limited announced the strengthening of the Board with the addition of a new non-executive director, Mr. Timothy Hughes. Mr. Hughes has significant experience in investment banking and finance from the senior positions he has held with Rothschilds Australia and within the superannuation industry and his experience as a director of various companies including Alchemia Ltd, Value Capital Management Pty Ltd. and South Endeavour Pty Ltd.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TIS:AU A$0.11 AUD +0.005

TIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TIS.
View Industry Companies

Industry Analysis


Industry Average

Valuation TIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TISSUE THERAPIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at